Aaron is Director of Central Business Development based in the Guangzhou office and has a leading role in the development of the Life Science and Health Care sector. Aaron is also supporting the firm's initiatives for the Greater Bay Area providing support to more closely link and develop Hong Kong, Macau, and the Guangdong Province. Before re-joining Deloitte in a business development role, Aaron was the Greater China Group Tax Manager for Procter & Gamble. In 10 years with Procter & Gamble, Aaron performed a multitude of roles including Transfer Pricing, Indirect Tax, Tax Controversy, Tax Planning, and M&A. Aaron was the Asia Leader for the divestiture of the Pringles business. Aaron has 20+ years of tax experience including 19 years in China.

Lareina Lau and women who have long been committed to sustainable development and are deeply involved in the fields of technology and investment have joined forces with all walks of life to launch a social innovation project, the Shero initiative, hoping that there will be more female power in the future of the diverse world. Currently, he is the CSR Special Assistant of Henderson (China) Investment Co., Ltd. and the Secretary-General of Fanyintang. He hopes that under the leadership of Dr. Li Jiajie, he can jointly promote the healthy development of youth education, technology for good, and ESG and other issues through a variety of innovative practical methods, and jointly achieve sustainable development of human society.

Engaged in the study of tumor cell fate evolution, he has published more than 20 SCI papers, including 10 papers as the first author or corresponding author in journals such as PNAS and Cancer Research, and 3 authorized patents. Selected into the 2018 China Postdoctoral Innovative Talent Support Program (Boxin Program), and as the project leader undertakes 1 national project, 4 provincial and ministerial projects, and 3 municipal projects.

Currently, he is a senior R&D scientist at Baiji Biopharmaceuticals, responsible for the development of pipelines related to anti-tumor immune cell therapy. Obtained a Ph.D. in Biology from Sun Yat-sen University. He was a postdoctoral researcher at Sun Yat-sen University’s Cancer Prevention and Treatment Center, where he was engaged in research on tumor-related myeloid cells. Relevant results have been published in journals such as Journal of Experimental Medicine, Journal of Clinical Investigation, and Frontier in Immunology as the first or co-author, and 3 patents have been applied for.

Chair professor of the School of Medicine at Southern University of Science and Technology, winner of the national talent title, computational systems biology and bioinformatics scholar. Joined the School of Medicine of Southern University of Science and Technology in January 2023. He was previously the "Board Professor" and "Georgia Science Association Distinguished Scholar Chair Professor" in the Department of Biochemistry at the University of Georgia (2003-2022), and the first director of the University of Georgia Institute of Physical Information (2003-2011). He has published nearly 400 academic papers and five books, including the world's first "Oncology Informatics" monograph, with more than 20,000 citations and an H-index of 71.

Professor Zhou Jingying graduated from the Institute of AIDS, Department of Microbiology, University of Hong Kong in 2013 with a PhD in microbiology. He then continued his postdoctoral research at the School of Biomedical Sciences at the Chinese University of Hong Kong (CUHK) and became a research assistant professor in 2018. He has published articles in many international journals, including Gut, Journal of Clinical Investigation, Cancer Research, Nature Communications, Nature Microbiology, etc. The current main research direction is the role of innate and adaptive immune regulation in cancer, and the main research direction is the tumor microenvironment mechanism of hepatocellular carcinoma (HCC), aiming to improve the level of cancer immunotherapy.

Since 2002, Wu Fushun has been committed to promoting sustainable social development with systematic thinking and big data algorithm technology. He is good at exploring the common goals of multiple stakeholders such as central and local governments, enterprises, and ordinary people, and promoting projects with economic and social benefits. He has deep professional knowledge and rich practical experience in the field of ESG (environmental, social and corporate governance). He actively promotes the integration of ESG into business innovation and integrates environmental, social and governance factors into investment decisions and corporate operations to achieve sustainable development concepts in investment and management.

Thalia Kong has extensive experience in Internet technology, cloud computing and smart city solutions. He has served as a senior executive in many multinational organizations, is familiar with market operations in the United States, China and Europe, and has nearly 20 years of international business experience. With extensive business and technical knowledge and resources, he has successfully coordinated and operated a number of complex multi-functional, multi-cultural, multi-enterprise/government relations projects. He has comprehensive and solid theoretical and practical experience in research and development, product life cycle management, sales and marketing, commercial operations, corporate planning, customer service, technology and process development, technology and personnel training, etc. Has more than 20 years of international business experience in customer pipeline penetration and management (5 years in Taiwan, 3 years in Singapore, +10 years in China and Europe).

Dr. Ho has been responsible for the commercialization of Longhuang series of soybeans since 2017. He was the first to introduce commercial tomato cultivation to Xinjiang and the first to introduce coffee cultivation to Yunnan. Dr. Ho has worked for large food and condiment companies such as Heinz, Kraft, and Lee Kum Kee, and is an active and well-known member of the Hong Kong Government's Food Safety Committee and Innovation and Technology Agency.

Millie Liu is the founding partner of the early-stage cutting-edge technologies-focused fund First Star Ventures. As an investor, she focuses her career on helping entrepreneurs with deep technology turn their ideas into great businesses with global reach. Some of her latest investments include MIT/Harvard/NASA spinouts applying computational approaches for novel protein design, CRISPR engineering, quantum-inspired materials design, long-range weather prediction, geothermal, etc.
Millie was previously at APT, an enterprise data analytics startup acquired by Mastercard for $600m where she helped Fortune 50 clients such as Walmart and P&G make better strategic decisions leveraging data. She was also the co-founder of an MIT startup working on unsupervised event detection, which later became Infervision, an AI precision healthcare platform that has raised over $200m from Sequoia, Goldman Sachs, etc. Millie is on the advisory board of MIT CSAIL (Computer Science and Artificial Intelligence Lab, the first AI lab in the world and the largest lab on MIT campus with over 1000 members). She holds a Master of Finance degree from MIT and a B.S. in Mathematics from the University of Toronto.

Ms. Wang Meijie is the CEO of Metanovas Biotech, an AI+ biotechnology company, focusing on building the world's leading new generation AI-driven functional raw material/product R&D and design platform. Ms. Wang Meijie has a master's degree in computer science in the field of AI. She also studied business at Stanford University's School of Management Engineering. He has published several papers in ACM and served as a judge for IEEE conferences. She once worked at NVIDIA's Silicon Valley headquarters for AI+ biological infrastructure research and development. She was the first Chinese engineer on NVIDIA's accelerated computing platform RAPIDS, and took the lead in promoting the cooperation between NVIDIA and Alibaba Cloud computing platforms. She worked on the research and development of medical artificial intelligence with Professor Li Feifei, a well-known AI scholar at Stanford University, and the entrepreneurial team at Stanford Medical School. The products she led the research and development were tested and used in Stanford Hospital. Today, as the founder and CEO of MetaNovas Yuanxing Intelligent Medicine, Ms. Wang Meijie’s enthusiasm for entrepreneurship has not diminished. Less than three years after the company was founded, the team has gathered academicians from the two academies and listed companies in the field of peptides in addition to the co-founders. The chief scientist of a pharmaceutical company, etc. The company has completed two rounds of financing, has several pending invention patents, and has cooperated with internationally renowned pharmaceutical companies (such as Japan's Takeda), leading cosmetics brands (L'Oreal) and functional food brands ( Such as Shancun's parent company Haleon) and others have established cooperation.

Ms. Chen June holds a bachelor's degree in finance and financial management from Northeastern University in the United States and a master's degree in international regulations on drugs and medical devices. She started her own medical device and drug import and export company and women's health company. As the assistant to the chairman of China's largest listed pharmaceutical company of steroid drugs, he was responsible for maintaining the company's core customers and medical resources, and led the completion of a cross-border merger and acquisition with an acquisition amount of 1.2 billion. In 2022, he was selected into Forbes China's Top 100 Young Returnees and led Ciyunge to win the fourth place in the world in the 2022 Peking University HSBC-Cambridge Judge Innovation and Entrepreneurship Competition.
Ciyunge Medical Technology Co., Ltd. focuses on the field of home real-time testing and cares about the health status of women and their families. It has now launched the "Banxiaolv" series of home quantitative testers to provide more families with professional and accurate digital real-time testing services. As well as supporting medical services, it comprehensively improves the diagnosis and treatment experience of specialized disease management and health management at home, allowing people to conveniently seek medical treatment at home and safeguarding a healthy life.

Dr. Cui holds doctorates in medical engineering and medical physics from MIT and Harvard Medical School. In terms of research on the construction of synthetic gene circuits and molecular systems, he has published many papers as the first author or contributing author in academic magazines such as Science, Nature Nanotechnology, and PNAS, and has obtained multiple patents for his research results. In 2019, he was selected as one of the "Global 30 Under 30" in the medical field by Forbes in the United States, and in 2020, he was selected as one of the "35 Technological Innovators Under 35" by MIT Technology Review.
Enhe Biotechnology is a biotechnology company based on the concept of synthetic biology. By creating a standardized automated high-throughput experimental operation platform and combining machine learning and artificial intelligence to systematically engineer organisms, we develop efficient, green, low-cost and applicable Focused on industrial biotechnology for large-scale production, it provides key technical solutions for various industries such as chemical, food, agriculture and pharmaceuticals. The company's core technology and management teams come from universities such as MIT and Harvard, as well as foundation companies in the field of synthetic biology such as Amyris, Ginkgo Bioworks, Zymergen, and Codexis. In 2020, it was successfully selected into the "MIT Technology Review" 50 Smart Companies, and in 2021, it was selected into the "List of 10 Startups Worth Watching in 2021" published by "C&EN" published by the American Chemical Society.

Gideon is the co-founder Enzymit and currently serves as its Chief Executive Officer. Gideon leads Enzymit's product and technology development and corporate strategy, he is also one of the key inventors behind Enzymit's design platform. Gideon holds a BSc in computer science from Tel-Aviv university and PhD in computational protein design from the Weizmann institute of science.
Enzymit is developing groundbreaking computational protein design algorithms based on fundamental discoveries in protein science amalgamated with cutting-edge experimental tools, augmented with deep-learning to create novel enzymes for novel chemistry.

Nurture was co-founded by Robert Green, MD, MPH, leader of the BabySEQ Project, whose evidence-driven work informs every aspect of Nurture’s service offering. BabySEQ1 was a landmark clinical study looking at newborn genetic risk markers. Later, the study’s findings were used to create a catalog of gene-disease associations, accelerating the real-world application of newborn genomic sequencing (NGS).
Dr. Green has led policy development for returning genomic information to research participants within the Global Alliance for Genomics and Health, the Verily-Google Baseline Project and the 1 million participants All of Us Research Program. He is co-founder of Genome Medical, a technology and service platform delivering telegenetics expertise throughout the US. Dr. Green leads the BabySeq Project, the first research to provide empirical data on the clinical utility and cost-effectiveness of genomic sequencing in healthy newborn infants, with the goal of establishing a responsible path to achieve universal human sequencing.

Rita graduated from MIT with an MBA from MIT Sloan School of Business, majoring in technological innovation, entrepreneurship and investment. A serial entrepreneur and investor in the field of technology, his focus on technology investment is hard technology, artificial intelligence digitization and low-carbon technology. He once served as COO of an AI quasi-unicorn company and deputy general manager of the innovation department of a leading consumer electronics company listed in Hong Kong.